title: The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection.
abstract: We have previously demonstrated that TNF-alpha levels are elevated in liver transplant patients experiencing acute rejection. In addition, prophylactic administration of anti-TNF-alpha or anti-TNF-beta antibodies prolonged graft survival in a rat heterotopic cardiac transplant model. This experiment was designed to evaluate anti-TNF therapy in the treatment of acute allograft rejection. Heterotopic cardiac transplants were performed using Buffalo donors and Lewis recipients. Histologic sections of transplanted grafts from untreated animals revealed significant rejection at day 4 with terminal rejection occurring on day 10.8 +/- 0.4. Animals in the experimental groups received antirejection therapy from postoperative days 4-13. Treatment with cyclosporine at 2 mg/kg/day prolonged graft survival to 16.5 +/- 2.0 days (P = 0.01 versus controls). Administration of polyclonal anti-TNF-alpha in combination with polyclonal anti-TNF-beta increased graft survival to 14.6 +/- 0.4 days (P less than 0.001 versus controls). Use of a monoclonal anti-TNF-alpha antibody was even more effective, with graft survival of 17.4 +/- 0.7 days (P less than 0.001 versus controls). Combination immunotherapy with monoclonal anti-TNF-alpha in conjunction with CsA extended survival to greater than 30 days. In contrast, recombinant TNF-alpha (5 micrograms/day, i.p.) markedly accelerated the time to graft failure (7.4 +/- 0.2 days, P less than 0.001 versus controls). Examination of explanted graft tissue on postoperative day 9 from animals treated with anti-TNF showed decreased mononuclear cell infiltrate when compared to untreated animals. Treatment with TNF-alpha markedly increased the inflammatory process. These results suggest that TNF may play a role in the pathogenesis of acute rejection.
authors.affiliation: Department of Surgery and Pathology, University of California, Los Angeles School of Medicine 90024.
authors.forename: D K
authors.initials: DK
authors.lastname: Imagawa
authors.forename: J M
authors.initials: JM
authors.lastname: Millis
authors.forename: P
authors.initials: P
authors.lastname: Seu
authors.forename: K M
authors.initials: KM
authors.lastname: Olthoff
authors.forename: J
authors.initials: J
authors.lastname: Hart
authors.forename: E
authors.initials: E
authors.lastname: Wasef
authors.forename: R A
authors.initials: RA
authors.lastname: Dempsey
authors.forename: S
authors.initials: S
authors.lastname: Stephens
authors.forename: R W
authors.initials: RW
authors.lastname: Busuttil
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D003524:Cyclosporins / Q000494:pharmacology; D006084:Graft Rejection; D006085:Graft Survival; D016027:Heart Transplantation; D008297:Male; D051381:Rats; D011915:Rats, Inbred BUF; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000276:immunology / Q000502:physiology*
chemical_list: D000906:Antibodies; D003524:Cyclosporins; D014409:Tumor Necrosis Factor-alpha